Journal Article

Spinal astrocyte dysfunction drives motor neuron loss in late-onset spinal muscular atrophy

Hagenacker, Tim, Leo, Markus, Schmitt, Linda-Isabell, Kleinschnitz, Christoph, Schara-Schmidt, Ulrike, Steffen, Rebecca, Roos, Andreas, David, Christina, Hezel, Stefanie

2023

Overview

Spinal muscular atrophy (SMA) is a progressive neuromuscular disorder caused by a loss of the survival of motor neuron 1 ( SMN1 ) gene, resulting in a loss of spinal motor neurons (MNs), leading to muscle weakness and wasting. The pathogenesis of MN loss in SMA and the selective vulnerability in different cellular populations are not fully understood. To investigate the role of spinal astrocytes in the pathogenesis of late-onset SMA, we used a mouse model in addition to in vitro approaches. Immunostaining, Western blot analysis, small interfering ribonucleic acid (siRNA) transfections, functional assays, enzyme-linked immunosorbent assay (ELISA), behavioral tests, and electrophysiological measurements were performed. Early activation of spinal astrocytes and a reduction of the excitatory amino acid transporter 1 (EAAT1) on postnatal day (P) 20 preceded the loss of spinal MNs in SMA mice occurring on P42. EAAT1 reduction resulted in elevated glutamate levels in the spinal cord of SMA mice at P20 and P42. SMA-like astrocytes generated by siRNA and an ex vivo model of glutamate excitotoxicity involving organotypic spinal cord slice cultures revealed the critical role of glutamate homeostasis in the degeneration of MNs. The pre-emptive administration of arundic acid (AA), as an inhibitor of astrocyte activation, to SMA mice prior to the loss of motor neurons (P28) resulted in elevated EAAT1 protein levels compared to vehicle-treated SMA mice and prevented the increase of glutamate in the spinal cord and the loss of spinal MNs. Furthermore, AA preserved motor functions during behavioral experiments, the electrophysiological properties, and muscle alteration of SMA mice. In a translational approach, we transfected healthy human fibroblasts with SMN1 siRNA, resulting in reduced EAAT1 expression and reduced uptake but increased glutamate release. These findings were verified by detecting elevated glutamate levels and reduced levels of EAAT1 in cerebrospinal fluid of untreated SMA type 2 and 3 patients. In addition, glutamate was elevated in serum samples, while EAAT1 was not detectable. Our data give evidence for the crucial role of spinal astrocytes in the pathogenesis of late-onset SMA, a potential driving force for MN loss by glutamate excitotoxicity caused by EAAT1 reduction as an early pathophysiological event. Furthermore, our study introduces EAAT1 as a potential therapeutic target for additional SMN-independent therapy strategies to complement SMN-enhancing drugs.

• Publisher: Springer Berlin Heidelberg,Springer,Springer Nature B.V
• Subject: Amino acids / Analysis / Animals / Astrocytes / Astrocytes - pathology / Cerebrospinal fluid / Degeneration / Disease Models, Animal / Drug development / Enzyme-linked immunosorbent assay / Enzymes / Excitatory amino acid transporters / Excitotoxicity / Fibroblasts / Glutamate / Glutamates - metabolism / Homeostasis / Humans / Medicine / Medicine & Public Health / Mice / Motor neurons / Motor Neurons - metabolism / Muscular Atrophy, Spinal - genetics / Nerve Degeneration - pathology / Neuromuscular diseases / Neurons / Neurosciences / Original Paper / Pathogenesis / Pathology / RNA, Small Interfering / siRNA / SMN protein / Spinal cord / Spinal muscular atrophy / Therapeutic targets